Crolll Gmbh   Report issue

For profit Phase 2 Phase 3
Founded: Nuremberg Germany (2015)

Organization Overview

First Clinical Trial
2015
NCT00775073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Crolll Gmbh

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Hepatocellular (Phase 2)

Edema (Phase 3)

Fatty Liver (Phase 2)

Graft vs Host Disease (Phase 2)

Liver Neoplasms (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pancreatic Neoplasms (Phase 3)

Thymoma (Phase 2)

Thymus Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 7